2019
DOI: 10.1158/0008-5472.can-19-0762
|View full text |Cite
|
Sign up to set email alerts
|

Are Platelets the Primary Target of Aspirin's Remarkable Anticancer Activity?

Abstract: Aspirin, when administered at low doses, has emerged as a powerful anticancer drug due to both chemopreventive activity against many forms of cancer and its ability to block metastases when administered postdiagnosis. Platelets, which are often elevated in circulation during the latter stages of cancer, are known to promote epithelial-mesenchymal transition , cancer cell growth, survival in circulation, and angiogenesis at sites of metastases. Low-dose aspirin has been demonstrated to block this procarcinogeni… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

2
19
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
9

Relationship

2
7

Authors

Journals

citations
Cited by 29 publications
(21 citation statements)
references
References 20 publications
2
19
0
Order By: Relevance
“…This coincides with a previous study, which demonstrated that activated platelets increased proliferation of colon cancer in both in vitro and in vivo mouse models, while treatment with aspirin and aspirin-PC decreased platelet counts and activation, which was correlated with decreased tumor burden (24). Platelet effects may account for the apparent effectiveness of aspirin against breast cancer in epidemiological studies despite the minimal direct antitumor effect of the drug in previous in vitro studies, which were performed in the absence of platelets (5,6,39). The authors of the present study aim to investigate the role of platelets and NSAID-induced platelet inhibition in breast cancer in future projects.…”
Section: Discussionsupporting
confidence: 90%
“…This coincides with a previous study, which demonstrated that activated platelets increased proliferation of colon cancer in both in vitro and in vivo mouse models, while treatment with aspirin and aspirin-PC decreased platelet counts and activation, which was correlated with decreased tumor burden (24). Platelet effects may account for the apparent effectiveness of aspirin against breast cancer in epidemiological studies despite the minimal direct antitumor effect of the drug in previous in vitro studies, which were performed in the absence of platelets (5,6,39). The authors of the present study aim to investigate the role of platelets and NSAID-induced platelet inhibition in breast cancer in future projects.…”
Section: Discussionsupporting
confidence: 90%
“…The anticancer effects of ASA have been previously discussed in the literature, but its actual therapeutic use is still controversial 18,46,47 . More is discussed about a putative chemopreventive action of ASA, such as its use to prevent myocardial infarct, and a reduced incidence of metastasis in cancer patients regularly taking the drug, than a direct effect reducing existent tumors 18,[46][47][48] . The results that we presented here showed that the treatment of mice with ASA, or even its metabolic product, SA, also prevented implanted cancer growth, which is beneficial especially when associated with other therapies.…”
Section: Discussionmentioning
confidence: 99%
“…In the current work, we showed that SA and ASA present anticancer effects against skin melanoma implanted on C57BL6/J mice. The anticancer effects of ASA have been previously discussed in the literature, but its actual therapeutic use is still controversial 18 , 46 , 47 . More is discussed about a putative chemopreventive action of ASA, such as its use to prevent myocardial infarct, and a reduced incidence of metastasis in cancer patients regularly taking the drug, than a direct effect reducing existent tumors 18 , 46 48 .…”
Section: Discussionmentioning
confidence: 99%
“…Long-term follow-up studies have shown that regular use of aspirin reduces the long-term risk of several cancers, as well as the risk of distant metastasis. [62][63][64] For lung cancer, the benefit of aspirin was only confirmed in ADC. 25 Anticoagulants are effective for patients with venous thromboembolism.…”
Section: Discussionmentioning
confidence: 99%